Safety and Tolerability Evaluation Study of BVAC-B in Patients With HER2/Neu(Human Epithelial Growth Factor Receptor 2) Positive Gastric Cancer After Failure to Standard Care

Inclusion Criteria: * Progressive or recurrent HER2/neu positive(IHC 1+≥) gastric cancer * Received 1 or more chemotherapy or radiotherapy as prior therapy for progressive or recurrent tumor lesion * At least 1 measurable lesion according to RECIST(ver 1.1) * Ages above 19 * ECOG performance status between 0 to 2 * Patients meets the blood test standards in the screening test * Patients meets the blood chemistry test standards in the screening test * Patients who has agreed to a medically accepted contraceptive in this clinical trial * Patients at least six months or more of survival can be expected * Patients decided to participate in this clinical trial and signed written informed consent Exclusion Criteria: * Histopathology is a neuroendocrine or small cell carcinoma * History of brain metastasis or signs of brain metastasis * Clinical diagnosis of hepatitis C or hepatitis B * Clinical diagnosis of human immunodeficiency virus (HIV) * History of HIV infection * Patients with heart failure, coronary artery disease(CAD) or Myocardial infarction in 6 month prior to screening. (LVEF is lower than 50% in screening visit) * Administered the drug for other clinical trials within 4weeks before participate in this trial * Administered any vaccines within 4weeks before participate in this trial (4 weeks for live vaccine, 2 weeks for other inactivated vaccine) * Administered the granulocytes concentrates within 3 months before the screening visit * Received chemotherapy or radiati…